Leerink Swann lowered shares of TESARO (NASDAQ:TSRO) from an outperform rating to a market perform rating in a report published on Monday morning, MarketBeat.com reports. The brokerage currently has $75.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $48.00.

A number of other research firms also recently commented on TSRO. Oppenheimer set a $83.00 price objective on TESARO and gave the stock a buy rating in a report on Thursday, November 1st. Cann restated a buy rating and set a $83.00 price objective on shares of TESARO in a report on Friday, November 2nd. Guggenheim started coverage on TESARO in a report on Monday, September 17th. They set a buy rating for the company. Cowen restated a hold rating and set a $38.00 price objective on shares of TESARO in a report on Monday, October 22nd. Finally, Bank of America upped their price objective on TESARO from $35.00 to $38.00 and gave the stock a neutral rating in a report on Tuesday, September 11th. Fifteen research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $78.18.

Shares of TESARO stock opened at $73.78 on Monday. TESARO has a fifty-two week low of $23.41 and a fifty-two week high of $85.48. The firm has a market cap of $4.06 billion, a price-to-earnings ratio of -8.05 and a beta of 1.49. The company has a debt-to-equity ratio of 3.74, a quick ratio of 2.83 and a current ratio of 3.40.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.62) by $0.13. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The company had revenue of $64.40 million for the quarter, compared to analyst estimates of $71.84 million. During the same quarter in the prior year, the company posted ($0.47) EPS. The business’s revenue for the quarter was down 54.9% compared to the same quarter last year. Analysts expect that TESARO will post -10.92 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV increased its holdings in TESARO by 20.0% in the 2nd quarter. KBC Group NV now owns 10,533 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 1,752 shares in the last quarter. Rhumbline Advisers increased its holdings in TESARO by 5.0% in the 2nd quarter. Rhumbline Advisers now owns 39,787 shares of the biopharmaceutical company’s stock valued at $1,769,000 after purchasing an additional 1,885 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in TESARO by 13.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 18,822 shares of the biopharmaceutical company’s stock valued at $734,000 after purchasing an additional 2,218 shares in the last quarter. US Bancorp DE increased its holdings in TESARO by 163.5% in the 3rd quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 2,445 shares in the last quarter. Finally, Xact Kapitalforvaltning AB increased its holdings in TESARO by 86.8% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 6,700 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 3,113 shares in the last quarter.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Read More: Are all No-Load Funds Equal?

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.